Last reviewed · How we verify
BMS-954561
BMS-954561 is a small molecule that targets the CD47/SIRPα axis.
BMS-954561 is a small molecule that targets the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | BMS-954561 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | CD47/SIRPα axis inhibitor |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BMS-954561 works by blocking the interaction between CD47 and SIRPα, which is a mechanism that cancer cells use to evade immune detection. This blockade allows the immune system to recognize and attack cancer cells more effectively.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Crossover Post-herpetic Neuralgia (PHN) (PHASE2)
- Diabetic Peripheral Neuropathic Pain (DPNP) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-954561 CI brief — competitive landscape report
- BMS-954561 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI